Description |
Jolkinolide A is a diterpenoid, can be extracted from the roots of Euphorbia fischeriana Steud. Jolkinolide A exhibits anti-tumor activity, by affecting on angiogenesis of tumor tissues. Jolkinolide A significantly inhibits the Akt-STAT3-mTOR signaling pathway and reduces the expression of VEGF in A549 cells[1].
|
Target |
VEGF[1]
|
In Vitro |
Jolkinolide A (20-100 μg/mL; 24 h) 提高 A549 细胞中 caspase-9 蛋白水平[1]。 Jolkinolide A (40-80 μg/mL; 24 h) 降低 A549 细胞中 Akt-STAT3-mTOR 蛋白的表达[1]。 Jolkinolide A (20-100 μg/mL; 24 h) 抑制人脐静脉内皮细胞 (HUVEC) 增殖和迁移,促进细胞凋亡[1]。 Western Blot Analysis[1] Cell Line: A549 cells Concentration: 20 μg/mL, 40 μg/mL, 60 μg/mL, 80 μg/mL, and 100 μg/mL Incubation Time: 24 hours Result: Promoted caspase-9 protein expression in cells at 20-100 μg/mL.Inhibited expression levels of Akt, STAT3, and mTOR proteins in cells at 40-80 μg/mL.
|
In Vivo |
Jolkinolide A (40 mg/kg; 腹腔注射; 每 3 天一次,持续 2 个月) 抑制小鼠A549细胞异种移植瘤模型中VEGF蛋白的表达[1]。 Animal Model: Female BALB/c nude mice (4-5 weeks old) injected with A549 cells[1] Dosage: 40 mg/kg Administration: Intraperitoneal injection; once every 3 days for 2 months Result: Significantly inhibited the expression of VEGF protein on the first, 10th, 30th, 45th, and 60th day of administration.
|
Density | 1.2±0.1 g/cm3 |
Boiling Point | 479.5±45.0 °C at 760 mmHg |
Flash Point | 206.7±23.3 °C |
Exact Mass | 314.188202 |
LogP | 4.70 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Storage condition | 2-8℃ |